Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
10.50
+0.45 (+4.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amicus Therapeutics
< Previous
1
2
3
Next >
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts
October 11, 2024
Via
Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
May 14, 2024
Via
Benzinga
This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today.
May 14, 2024
Via
Benzinga
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Amicus Therapeutics Stock Sees RS Rating Improve To 74
March 05, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Via
Investor's Business Daily
The Analyst Landscape: 4 Takes On Amicus Therapeutics
December 19, 2023
Via
Benzinga
Amicus Therapeutics: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
The Latest Analyst Ratings for Amicus Therapeutics
March 28, 2023
Via
Benzinga
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
February 09, 2024
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday.
Via
Investor's Business Daily
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
November 15, 2023
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
September 29, 2023
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
September 28, 2023
The FDA has approved Amicus Therapeutics' (NASDAQ: FOLD) Pombiliti (cipaglucosidase alfa-atga)+Opfolda (miglustat) 65mg capsules for Pompe disease.
Via
Benzinga
Exposures
Product Safety
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Earnings Preview: Amicus Therapeutics
February 28, 2023
Via
Benzinga
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
October 31, 2022
Via
Benzinga
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade
July 20, 2023
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81.
Via
Investor's Business Daily
Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating
July 17, 2023
On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier.
Via
Investor's Business Daily
Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark
May 19, 2023
One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday.
Via
Investor's Business Daily
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
May 10, 2023
The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult
Via
Benzinga
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
January 25, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec.
Via
Benzinga
Recap: Amicus Therapeutics Q3 Earnings
November 07, 2022
Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.
Via
Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
August 08, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.